IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v12y2021i1d10.1038_s41467-021-20973-3.html
   My bibliography  Save this article

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity

Author

Listed:
  • Matthias Becker

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Monika Strengert

    (Helmholtz Centre for Infection Research
    TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research)

  • Daniel Junker

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Philipp D. Kaiser

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Tobias Kerrinnes

    (Helmholtz-Institute for RNA-based Infection Research (HIRI))

  • Bjoern Traenkle

    (NMI Natural and Medical Sciences Institute at the University of Tübingen
    University of Tübingen)

  • Heiko Dinter

    (NMI Natural and Medical Sciences Institute at the University of Tübingen
    University of Tübingen)

  • Julia Häring

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Stéphane Ghozzi

    (Helmholtz Centre for Infection Research)

  • Anne Zeck

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Frank Weise

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Andreas Peter

    (University Hospital Tübingen
    Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen
    German Center for Diabetes Research (DZD))

  • Sebastian Hörber

    (University Hospital Tübingen
    Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tübingen
    German Center for Diabetes Research (DZD))

  • Simon Fink

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Felix Ruoff

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Alex Dulovic

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Tamam Bakchoul

    (University Hospital Tübingen)

  • Armin Baillot

    (Niedersächsisches Landesgesundheitsamt, Department of Virology/Serology)

  • Stefan Lohse

    (Saarland University Medical Center)

  • Markus Cornberg

    (Hannover Medical School, Hannover, Germany; Centre for Individualized Infection Medicine (CiiM))

  • Thomas Illig

    (Hannover Unified Biobank (HUB), Hannover Medical School)

  • Jens Gottlieb

    (Hannover Medical School
    Biomedical Research in End-stage and obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL))

  • Sigrun Smola

    (Saarland University Medical Center)

  • André Karch

    (University of Münster)

  • Klaus Berger

    (University of Münster)

  • Hans-Georg Rammensee

    (University of Tübingen
    German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen
    Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen)

  • Katja Schenke-Layland

    (NMI Natural and Medical Sciences Institute at the University of Tübingen
    Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
    Eberhard-Karls-University
    David Geffen School of Medicine at UCLA)

  • Annika Nelde

    (University of Tübingen
    Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
    University Hospital Tübingen)

  • Melanie Märklin

    (Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
    David Geffen School of Medicine at UCLA)

  • Jonas S. Heitmann

    (Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
    David Geffen School of Medicine at UCLA)

  • Juliane S. Walz

    (University of Tübingen
    Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen
    University Hospital Tübingen
    Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology (IKP) and Robert Bosch Center for Tumor Diseases (RBCT))

  • Markus Templin

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Thomas O. Joos

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

  • Ulrich Rothbauer

    (NMI Natural and Medical Sciences Institute at the University of Tübingen
    University of Tübingen)

  • Gérard Krause

    (Helmholtz Centre for Infection Research
    TWINCORE GmbH, Centre for Experimental and Clinical Infection Research, a joint venture of the Hannover Medical School and the Helmholtz Centre for Infection Research)

  • Nicole Schneiderhan-Marra

    (NMI Natural and Medical Sciences Institute at the University of Tübingen)

Abstract

The humoral immune response to SARS-CoV-2 is a benchmark for immunity and detailed analysis is required to understand the manifestation and progression of COVID-19, monitor seroconversion within the general population, and support vaccine development. The majority of currently available commercial serological assays only quantify the SARS-CoV-2 antibody response against individual antigens, limiting our understanding of the immune response. To overcome this, we have developed a multiplex immunoassay (MultiCoV-Ab) including spike and nucleocapsid proteins of SARS-CoV-2 and the endemic human coronaviruses. Compared to three broadly used commercial in vitro diagnostic tests, our MultiCoV-Ab achieves a higher sensitivity and specificity when analyzing a well-characterized sample set of SARS-CoV-2 infected and uninfected individuals. We find a high response against endemic coronaviruses in our sample set, but no consistent cross-reactive IgG response patterns against SARS-CoV-2. Here we show a robust, high-content-enabled, antigen-saving multiplex assay suited to both monitoring vaccination studies and facilitating epidemiologic screenings for humoral immunity towards pandemic and endemic coronaviruses.

Suggested Citation

  • Matthias Becker & Monika Strengert & Daniel Junker & Philipp D. Kaiser & Tobias Kerrinnes & Bjoern Traenkle & Heiko Dinter & Julia Häring & Stéphane Ghozzi & Anne Zeck & Frank Weise & Andreas Peter & , 2021. "Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity," Nature Communications, Nature, vol. 12(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-20973-3
    DOI: 10.1038/s41467-021-20973-3
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-021-20973-3
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-021-20973-3?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-20973-3. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.